Interferon (IFN) resistance is an important factor in the pathophysiology of neoplastic disorders, certain viral infections (e.g., AIDS), and autoimmune diseases (e.g., lupus erythematosus and Wegner's granulomatosis). In addition, in some of these disorders, there is also decreased ability to produce IFNs. The capacity of viruses and neoplastic processes to interfere with the IFN system are thought to represent a “virus-against-host” or “cancer-against-host” defense mechanism. Four resistance factors have been identified: 1) release of free IFN-α/β type 1 receptors into the circulation that, at appropriate concentrations, capture and inactivate IFNs; 2) a new IFN inhibitory protein has been isolated and its chemical structure is under study; 3) prostaglandin E2, which is produced by certain tumor cells, inhibits IFN production; and 4) high levels of cAMP phosphodiesterases present, for example in certain tumor cells, reduces cAMP, an important second messenger in IFN synthesis. Studies are under way to reverse these inhibitory effects and to increase endogenous interferon production.
IkossiMG, AmbrusJL, ChadhaKC. Regulation of in vitro human leukocyte interferon production: effect of prostaglandin synthetase and phosphodiesterase inhibition. Res Commun Chem Pathol Pharmacol54:379–384, 1986.
2.
ChadhaKC, AmbrusJL, HalpernJ, KhalilM, SayyidS, PiverMS, HreshchyshynMM. The interferon system in carcinoma of the cervix: effect of radiation and chemotherapy. Cancer67:87–90, 1991.
3.
ChadhaKC, AmbrusJL, IkossiMG. Interferons and interferon inactivators in AIDS, ARC and in cancer patients. In:CantellK, SchellekensH, Eds. The Biology of the Interferon System, 1986. Proceedings of the 1986 ISIR-TNO Meeting on the Interferon System. September 7–12, 1986, Helsinki, Finland: Martinus Nijoff, pp423–427, 1987.
4.
AmbrusJL, ChadhaKC, AnthoneS, AnthoneR, SayyidS.The alpha-interferon system in patients undergoing renal transplantation and treated with cyclosporine and prednisone. Surg Gynecol Obstet176:588–590, 1993.
5.
StefanovichV, AmbrusJL, AmbrusCM, KarakousisC, TakitaH.Cyclic nucleotide phosphodiesterases in normal and malignant human tissue. J Med12:243–250, 1981.
6.
AmbrusJL, StollJL, KleinE, KarakousisCP, StadlerS.Increased prostaglandin E2 and cAMP phosphodiesterase levels in Kaposi's sarcoma: a virus-against-host defense mechanism. Res Commun Chem Pathol Pharmacol78:249–252, 1992.
7.
AttallahA, LeeJB, AmbrusJL, AmbrusCM, KarakousisCP, TakitaH.Prostaglandin E2 production by human tumors: defense mechanism against the host. Res Commun Chem Pathol Pharmacol43:195–201, 1984.
8.
StadlerI, KapuiZ, AmbrusJL. Study on the mechanisms of action of sodium meclofenamic acid (Meclomen), a “double inhibitor” of the arachidonic acid cascade. J Med25:371–382, 1994.
9.
MahafzahM, StadlerS, AmbrusJL, ChadhaKC. Effect of meclomen on production and action of human interferon alpha. Acta Virol34:27–36, 1990.
10.
StadlerS, ChadhaKC, NakeebS, ToumbisC, ButschJ, MathurN, MunschauerF, VladutiuA, AmbrusJL. Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. J Pharmacol Exp Ther268:10–13, 1994.
11.
AszalosA, GrimleyPM, BalintE, ChadhaKC, AmbrusJL. On the mechanisms of action of interferons: interaction with nonsteroidal, anti-inflammatory agents pentoxifylline (Trental) and cGMP and inducers. J Med22:255–271, 1991.
12.
BiddleW, LeongSS, HoroszewiczJ, AmbrusJL. Potentiation of the cell growth inhibitory effect of β-interferon by mopidamole. Proc Soc Exp Biol Med177:487–490, 1984.
13.
SikoraK, Ed. Interferon and Cancer. New York: Plenum Press, 1983.
14.
GuttermanJ.Cytokine therapeutics: lessons from interferon-α. Proc Natl Acad Sci U S A91:1198–1205, 1996.
15.
PithaPM. Introduction of interferon's connection to cancer. Semin Cancer Biol10:69–72, 2000.
16.
EinhornS, GranderD.Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res16:275–281, 1996.
17.
EinhornS, StranderH.Interferon treatment of human malignancies: a short review. Med Oncol Tumor Pharmacother10:25–29, 1993.
18.
Ikossi-O'connorMG, AmbrusJL, WestT, LillieMA, MilgromH, ChadhaKC. Interferon and interferon inactivators in patients with acquired immune deficiency syndrome and Kaposi's sarcoma. Res Commun Chem Pathol Pharmacol45:271–277, 1984.
19.
TsantakisG, SchizasN, HarvedakiM.Interferon inhibitors and/or inactivators in sera from patients with neoplasias. Arch Immunol Ther Exp41:335–337, 1993.
20.
CesarioT, VaziriN, TillesJ.Inactivators of fibroblast interferon found in human serum. Infect Immun24:851–855, 1979.
21.
KarmaniolasKD, PapalamprosTS, PapavassiliouED, LiatisSTh, KalantzisN.Detection of interferon inhibitors or antagonists in gastrointestinal malignancies. Hepatogastroenterology45:2244–2247, 1998.
22.
AmbrusJL, PoieszBJ, LillieMA, StadlerS, DiBemardinoL, ChadhaKC. Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, AIDS, ARC, Kaposi's sarcoma and normal individuals. Am J Med87:405–407, 1998.
23.
O'connorMGI, ChadhaKC, LillieMA, StadlerS, BernsteinZ, Zucker-FranklinD, AmbrusJL. Interferon inactivator(s) in patients with AIDS and AIDS-related Kaposi's sarcoma. Am J Med81:783–786, 1986.
24.
HarmonMW, GreenbergSB, CouchRB. Effect of human nasal secretions on the antiviral activity of human fibroblast and leukocyte interferon. Proc Soc Exp Biol Med152:598–602, 1976.
25.
NovickD, EngelmannH, WallachD, RubinsteinM.Soluble cytokine receptors are present in normal human urine. J Exp Med170:1409–1414, 1989.
26.
NovickD, CohenB, RubinsteinM.Soluble interferon-alpha receptor molecules are present in body fluids. Fed Eur Biochem Soc314:445–448, 1992.
27.
HavredakiM, BaronaF.Variations of interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn J Med Sci Biol38:107–111, 1985.
28.
AmbrusJL, AmbrusJLJr, ChadhaS, NovickD, RubinsteinM, GopalakrishnanB, BernsteinZ, PrioreR, ChadhaKC. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res Commun Mol Pathol Pharmacol96:255–265, 1997.
29.
AmbrusJL, AmbrusJLJr, ChadhaKC. Interferon inhibitors in lupus erythematosus. N Engl J Med319:582–583, 1986.
30.
ChadhaKC, AmbrusJL, StadlerS, AmbrusJLJr.Interferon inhibitor in the blood of patients with systemic lupus erythematosus. J Biol Regul Homeost Agents5:1–9, 1991.
31.
AmbrusJL, ChadhaKC, AmbrusJLJr.Interferon inhibitors in Wegner's granulomatosis. Ann Intern Med114:606–607, 1991.
32.
ChadhaKC, AmbrusJL, HalpernJ, KhalilM, PiverMS, HreshchyshynMM. The interferon system in gynecologic cancer: effect of radiation and chemotherapy. Cancer67:87–91, 1991.
33.
FinterNB. Dye uptake method of assessing viral cytopathogenicity and their application to interferon assays. J Gen Virol5:419–427, 1969.
34.
PayneJ, NairMPN, AmbrusJL, ChadhaKC. Mild hyperthermia modulates biological activities of interferons. Int J Hyperthermia16(6):492–507, 2000.
35.
AmbrusJL, ChadhaKC, AmbrusJLJr.Interferon inhibitors. Ann Intern Med114:606–607, 1991.
36.
HardyMP, OwczarekCM, TrajanovskaS, LiuX, KolaI, HertzogPJ. The soluble murine type 1 interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood97:473–482, 2001.
37.
MoosmayerD, GerlachE, HauffR, BeckerP, BrocksB, PfizenmaierK.A bivalent immunoadhesion of the human interferon-gamma receptor is an effective inhibitor of IFN-gamma activity. J Interferon Cytokine Res15:1111–1115, 1995.
BaslerCF, WangX, MuhlbergerE, VolchkovV, ParagasJ, KlenkH-D. The Ebola virus VP35 protein functions as a type 1 IFN antagonist. Proc Natl Acad Sci U S A97:12289–12294, 2000.
41.
AmbrusJL, DembinskiW, AmbrusJLJr, SykesDE, AkhterS, KulaylatMN, IslamA, ChadhaKC. Free interferon-α/β receptors in the circulation of patients with adenocarcinomas. Cancer98:2730–2733, 2004.
42.
NovickD, EngelmannH, LeitnerO, RubinsteinM.Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma10:137–146, 1991.
43.
NovickD, EngelmannH, WallachD, LeitnerO, RevelM, RubinsteinM.Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr510:331–337, 1990.
44.
AmbrusJL, IslamA, AkhterS, KulaylatM, SykesD, DembinskiW, BardosTJ, AradiJ, ChadhaP, ChadhaKC. New potent interferon inducing agents: Thiolated poly (I). Poly (MPC). Proceedings of Spring Clinical Day, State University of New York at Buffalo, pp1–10, 1999.
45.
NakamuraH, LiM, ZaryckiJ, JungJU. Inhibition of P53 tumor suppressor by viral interferon regulatory factor. Virology75:7572–7582, 2001.
46.
ZhuFX, KingSM, SmithEJ, LevyDE, YuanY.A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type 1 interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci U S A99:5573–5578, 2002.
47.
PooleLJ, YuY, KimPS, ZhengQZ, PevsnerJ, HaywardGS. Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus. J Virol76:3395–3420, 2002.
48.
KirchoffV, WongS, StJS, PariGS. Generation of a life-expanded rhesus monkey fibroblast cell line for the growth of rhesus rhadinovirus (RRV). Arch Virol147:321–333, 2002.
49.
DaubenerW, NockemannS, GubscheM, HaddingU.Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-gamma. Eur J Immunol25:688–692, 1995.
50.
DaubenerW, GutscheM, NockemannS.Protamine enhances the activity of human recombinant interferon-γ. J Interferon Cytokine Res16:531–536, 1996.
